NanoVibronix, Inc. (NAOV)
Pre-market:
| Previous close | 0.7425 |
| Open | 0.7230 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.6775 - 0.7538 |
| 52-week range | 0.6775 - 4.3400 |
| Volume | |
| Avg. volume | 64,575 |
| Market cap | 1.921M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1200 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract Award
ELMSFORD, N.Y., May 01, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective May 1, 2024, the Company’s PainShield product will be included in the U.S. Department of Veteran Affairs’ ("VA") Federal Supply Schedule ("FSS"), a program that supports the healthcare acquisition needs of the VA and
- Business Wire
NanoVibronix Issues Letter to Stockholders
ELMSFORD, N.Y., April 09, 2024--NanoVibronix, Inc., (NASDAQ: NAOV)("NanoVibronix"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the fourth quarter and full year 2023 and recent business developments.
- Business Wire
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
ELMSFORD, N.Y., March 28, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company’s next generation UroShield and PainShield products.
